IP Library Granted Patent US 7,994,293
Granted Patent B2
US 7,994,293 · App. 12/012,885 · Granted Aug 9, 2011

Antibodies specific for Dkk-1

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,994,293
App. No.
12/012,885
Granted
Aug 9, 2011
Kind
B2
Abstract

Antibodies specific for Dkk-1, an inhibitor of the osteoanabolic Wnt/LRP5 signaling pathway, are described. The antibodies, which inhibit binding of Dkk-1 to LRP5, are useful in compositions for stimulating bone growth, in particular, compositions for treating bone disorders which result in a loss in bone, for example, osteoporosis.

Claims (23)

1. An isolated monoclonal antibody that specifically binds a mature human Dkk-1 protein consisting of amino acids 32-266 of SEQ ID NO: 35 and having a tertiary structure established by a disulfide bond between cysteine residues 220 and 245, wherein the antibody binds to an epitope within a loop consisting of the amino acids between cysteine residues 201 and 210 of SEQ ID NO: 35.

2. The isolated antibody of claim 1 that is a human or humanized antibody.

3. An isolated monoclonal antibody or that competes with the antibody of claim 1 for specific binding to a Dkk-1 polypeptide.

4. The isolated antibody claim 3 that competes with an antibody that consists of two identical heavy chains and two identical light chains, wherein the heavy chains consist of the amino acid sequence set forth in SEQ ID NO: 3 and the light chains consist of the amino acid sequence set forth in SEQ ID NO: 7.

5. The isolated antibody claim 4 that dissociates from the Dkk-1 polypeptide with a Kd of about 269 pM or less.

6. An isolated antibody that binds to human Dkk-1, wherein

(a) the heavy chain variable region of said antibody comprises CDR1, CDR2 and CDR3 amino acid sequences as set forth in SEQ ID NO: 9, SEQ ID NO: 10 and SEQ ID NO: 11 respectively; and

(b) the light chain variable region of said antibody comprises CDR1, CDR2 and CDR3 amino acid sequences as forth in SEQ ID NO: 12, SEQ ID NO: 13 and SEQ ID NO: 14 respectively.

7. The isolated antibody of claim 6 , wherein said antibody specifically binds a mature human Dkk-1 protein consisting of amino acids 32-266 of SEQ ID NO: 35 and having a tertiary structure established by a disulfide bond between cysteine residues 220 and 245, wherein the antibody binds to an epitope comprising a loop consisting of the amino acids between cysteine residues 201 and 210 of SEQ ID NO: 35.

8. An isolated antibody that binds to human Dkk-1, wherein

(a) the heavy chain variable region of said antibody comprises CDR1, CDR2 and CDR3 amino acid sequences as set forth in SEQ ID NO: 67, SEQ ID NO: 68 and SEQ ID NO: 69 respectively; and

(b) the light chain variable region of said antibody comprises CDR1, CDR2 and CDR3 amino acid sequences as forth in SEQ ID NO: 12, SEQ ID NO: 13 and SEQ ID NO: 61 respectively.

9. An isolated antibody that binds to human Dkk-1, wherein

(a) the heavy chain variable region of said antibody comprises CDR1, CDR2 and CDR3 amino acid sequences as set forth in SEQ ID NO: 9, SEQ ID NO: 10 and SEQ ID NO: 11 respectively; and

(b) the light chain variable region of said antibody comprises CDR1, CDR2 and CDR3 amino acid sequences as forth in SEQ ID NO: 12, SEQ ID NO: 62 and SEQ ID NO: 63 respectively.

10. An isolated antibody that binds to human Dkk-1, wherein

(a) the heavy chain variable region of said antibody comprises CDR1, CDR2 and CDR3 amino acid sequences as set forth in SEQ ID NO: 9, SEQ ID NO: 10 and SEQ ID NO: 11 respectively; and

(b) the light chain variable region of said antibody comprises CDR1, CDR2 and CDR3 amino acid sequences as forth in SEQ ID NO: 64, SEQ ID NO: 65 and SEQ ID NO: 66 respectively.

11. An isolated antibody that binds to human Dkk-1 comprising

(a) a heavy chain variable region which comprises CDR1, CDR2, and CDR3 amino acid sequences as set forth in SEQ ID NO: 9, SEQ ID NO: 10 and SEQ ID NO: 11 respectively; and

(b) a light chain variable region selected from the group consisting of SEQ ID NO: 4, SEQ ID NO: 48 and SEQ ID NO: 49.

12. The isolated antibody of claim 10 , wherein the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO: 8.

13. An isolated antibody that binds to human Dkk-1 and has a VL and VH pair selected from SEQ ID NO: 47 in combination with SEQ ID NO: 58; SEQ ID NO: 4 in combination with SEQ ID NO: 8; SEQ ID NO: 48 in combination with SEQ ID NO: 59 and SEQ ID NO: 49 in combination with SEQ ID NO: 60.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 30, 2014
From: MERCK SHARP & DOHME CORP.
To: MEDIMMUNE LIMITED
Reel/Frame 032992/0795 →
CHANGE OF NAME Recorded Aug 29, 2012
From: SCHERING CORPORATION
To: MERCK SHARP & DOHME CORP.
Reel/Frame 028866/0511 →
MERGER Recorded Aug 27, 2012
From: MERCK SHARP & DOHME CORP.
To: SCHERING CORPORATION
Reel/Frame 028850/0515 →
CHANGE OF NAME Recorded Jan 26, 2010
From: MERCK & CO., INC.
To: MERCK SHARP & DOHME CORP.
Reel/Frame 023906/0803 →